MIT scientists implanted oxygen-producing devices with insulin-making cells in mice and rats; the cells remained active for at least 90 days and helped control blood sugar

A groundbreaking study reveals a new wireless device aimed at improving diabetes treatment by fostering the functionality of insulin-producing cells. This innovative technology enables these cells to effectively produce insulin for as long as 90 d...

An AI-generated image of a researcher carefully positioning a miniature insulin-producing cell implant beneath the skin of a laboratory mouse during a biomedical experiment. Image credits: ChatGPT


Between paying rent, replying to work emails, and worrying about your phone only being at 12% battery, many in the US struggle to keep on top of their to-do lists. However, for many with diabetes, this includes regular blood sugar checks and insulin injections. According to MIT News, most people will need to frequently check their blood sugar levels and inject insulin. However, researchers are constantly looking for ways to help.

In a March 2026 study titled “Wireless battery-free oxygenation devices enable extended immunosuppression-free islet transplantation in minimally invasive sites,” published in the journal Device, researchers found that insulin-producing cells within a small implant, with an oxygen-producing mechanism, stayed alive and active for at least 90 days inside rats and mice, which is long enough for them to produce enough insulin to keep blood sugar levels regulated throughout that period. Whilst you won’t be able to go to your next doctor’s appointment asking about this, as it hasn’t been trialled on humans yet, it is a pretty clever piece of technology.

Cell therapy isn’t brand new, but it comes with baggage


According to the CDC, there are around 2.1 million people with diagnosed type 1 diabetes in the US. This includes around 1.8 million adults over the age of 20, and 314,000 children and adolescents under 20. Replacing the cells with ones that produce insulin is not new, and there is even a treatment available. The FDA approved Lantidra as the first cell treatment for type 1 diabetes in June 2023.

Image 2026-11-16 at 18
<p>Blood glucose testing by a blood glucose meter. Image credits: Wikimedia Commons<br></p>
Per the FDA, Lantidra is indicated for adults with type 1 diabetes who experience recurrent severe hypoglycemic events despite intensive diabetes management. It is derived from pancreatic cells obtained from deceased donors. However, in a majority of trials involving the treatment, serious adverse reactions occurred in participants related to the infusion and immunosuppressive medications. This is because islet cell transplants require immunosuppressive medication to survive. It can be very harsh on some patients, as noted by the study’s senior author, Daniel Anderson.

The oxygen problem
ADVERTISEMENT

MIT News reports that cells can be protected from immune rejection using a protective device; however, this can mean the cells don’t get enough oxygen. To solve this issue, the team created an oxygen-producing device. Using a proton exchange membrane, water vapour, which is abundant in the body, can be separated into hydrogen and oxygen. The hydrogen floats away without any issues, and the oxygen is stored in a chamber. From here, it can be transported to the cells via a thin membrane. In 2023, the team originally reported that cells within the device produced insulin for up to a month in mice.

What changed this time

The team has improved the device to become more waterproof and less likely to crack. They have also improved the electronics within the device to allow more power to reach the oxygen-producing device. The implant is powered by an external antenna on the skin via wireless power, like how your phone can be charged wirelessly.

Image 2026-11-16 at 18
<p>Laser scanning confocal microscopic view of Islet of Langerhans isolated from rat pancreas. Image credits: Wikimedia Commons<br></p>
This meant more power could be used to produce oxygen, allowing the cells to produce much more insulin. This device functioned for at least 90 days in rats and mice. According to MIT News, the cells from the donor islet cells kept their blood sugar levels within a healthy range. Islet cells derived from induced pluripotent stem cells showed similarly durable survival and function inside the device. However, while these stem-cell-derived islets also helped regulate blood sugar, they weren’t able to fully reverse diabetes, offering meaningful but partial glycemic control rather than complete normalization, similar to the donor-cell results.
ADVERTISEMENT

The final notes

Whilst this is a massive improvement from a month to 90 days, it is still a short period of time. As per MIT News, the team now wants to see if they can increase the lifespan of the devices to up to 2 years. They are also looking into how this can be used to deliver other protein-producing cells.
Download
The Economic Times Business News App
for the Latest News in Business, Sensex, Stock Market Updates & More.
Download
The Economic Times News App
for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
READ MORE
ADVERTISEMENT

READ MORE:

LOGIN & CLAIM

50 TIMESPOINTS

More from our Partners

Loading next story
Business News › News › International › US News › MIT scientists implanted oxygen-producing devices with insulin-making cells in mice and rats; the cells remained active for at least 90 days and helped control blood sugar
Text Size:AAA
Success
This article has been saved

*

+